CVE-2012-1032: Cross-site scripting (XSS) vulnerability in the Euroling SiteSeeker module 3.x before 3.4.5 for EPiServer allo
CVE-2012-1032 is a medium-severity flaw (CVSS 4.3) affecting euroling siteseeker, episerver. Below: why it ranks where it does, which versions are affected, what to do, and the exact commands.
Cross-site scripting (XSS) vulnerability in the Euroling SiteSeeker module 3.x before 3.4.5 for EPiServer allows remote attackers to inject arbitrary web script or HTML via unspecified vectors. NOTE: the provenance of this information is unknown; the details are obtained solely from third party information.
Why this priority
- No elevated risk signals yet
No fix is published yet: follow the downgrade or mitigation steps.
Risk facts
| CVSS score | 4.3 (Medium) |
| EPSS exploit chance | 1.2% (top 33%) |
| CISA exploited list | No |
| Weakness | CWE-79 |
| Published | 2014-09-17 |
| Last modified | 2026-06-16 |
Last updated 2026-06-16 · Sources: CVE Program, NVD, CISA KEV, EPSS and vendor advisories · How we score
Am I affected?
Timeline
- Published CVE record published
- Updated Record last modified
Scores and fixes here are computed automatically from those and other public sources. Confirm with the vendor advisory before changing production systems.
Quick answers
How do I fix CVE-2012-1032?
euroling siteseeker: downgrade or apply the listed mitigation; episerver: mitigate or apply the listed mitigation. Exact commands for each OS are on this page.
Is CVE-2012-1032 being exploited?
CVE-2012-1032 is not on the CISA Known Exploited Vulnerabilities list at the time of the last update. Check again, as this can change.
What does CVE-2012-1032 affect?
CVE-2012-1032 affects euroling siteseeker, episerver. Severity is medium (CVSS 4.3). Cross-site scripting (XSS) vulnerability in the Euroling SiteSeeker module 3.x before 3.4.5 for EPiServer allows remote attackers to inject arbitrary web script or HTML via unspecified vectors. NOTE: the provenance of this information is u
How urgent is CVE-2012-1032?
Priority 32/100. No elevated risk signals yet.